Synapse

← Global & Regional Health Technology Assessment

Papers in Global & Regional Health Technology Assessment

Page 2 · newest first

  1. Economic impact of dapagliflozin in the management of chronic kidney disease in Italy: results from a micro-simulation modelGlobal & Regional Health Technology Assessment · 2024
  2. Policy predictive model for better management of chronic obstructive pulmonary disease: economic-organisational implications in the Italian healthcare systemGlobal & Regional Health Technology Assessment · 2024
  3. A cost-effectiveness analysis of Navina Smart on adult patients affected by neurogenic bowel dysfunctionGlobal & Regional Health Technology Assessment · 2024
  4. The economic and social burden of congenital thrombotic thrombocytopenic purpura (cTTP) in ItalyGlobal & Regional Health Technology Assessment · 2024
  5. Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian studyGlobal & Regional Health Technology Assessment · 2024
  6. Budget impact analysis on the Italian healthcare system of roxadustat for the treatment of anemia due to chronic kidney diseaseGlobal & Regional Health Technology Assessment · 2024
  7. Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease networkGlobal & Regional Health Technology Assessment · 2024
  8. Usefulness of dalbavancin in early discharge and non-hospitalization. It’s time to throw your heart over the obstacle?Global & Regional Health Technology Assessment · 2024
  9. Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overviewGlobal & Regional Health Technology Assessment · 2024
  10. Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panelGlobal & Regional Health Technology Assessment · 2024
  11. Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databasesGlobal & Regional Health Technology Assessment · 2024
  12. Exploring the administrative burden faced by hematologists: a comprehensive study in ItalyGlobal & Regional Health Technology Assessment · 2024
  13. Early access programs for medicines: a reform proposal for the Italian National Health ServiceGlobal & Regional Health Technology Assessment · 2024
  14. Gender differences and hypercholesterolemia: real-world evidence from the study WECARE (Women Effective CArdiovascular Risk Evaluation)Global & Regional Health Technology Assessment · 2024
  15. How effective are prescriptive governance tools? Results from the application of AIFA notesGlobal & Regional Health Technology Assessment · 2024
  16. Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholdersGlobal & Regional Health Technology Assessment · 2024
  17. The economic impact of 14 compassionate use programs for medicines in Italy, in the perspective of the National Health ServiceGlobal & Regional Health Technology Assessment · 2024
  18. Patient-reported outcomes in epilepsy: a case study exploring their usage and impactGlobal & Regional Health Technology Assessment · 2024
  19. Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in ItalyGlobal & Regional Health Technology Assessment · 2024
  20. Regional administrative data and their role in planning, programming and controlling at regional levelGlobal & Regional Health Technology Assessment · 2024
  21. Heart failure and economic impact: an analysis in real clinical practice in ItalyGlobal & Regional Health Technology Assessment · 2024
  22. The socioeconomic burden of adult attention-deficit/hyperactivity disorder in SpainGlobal & Regional Health Technology Assessment · 2024
  23. The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical exampleGlobal & Regional Health Technology Assessment · 2024
  24. Regional Formularies in Italy: current state and future perspectivesGlobal & Regional Health Technology Assessment · 2024
  25. Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitisGlobal & Regional Health Technology Assessment · 2024
  26. HTA regulation: how is Italy moving?Global & Regional Health Technology Assessment · 2024
  27. Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in ItalyGlobal & Regional Health Technology Assessment · 2024
  28. Clinical and economic burden of peristomal skin complications: Activity Based Costing analysisGlobal & Regional Health Technology Assessment · 2024
  29. A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomasGlobal & Regional Health Technology Assessment · 2024
  30. Orphan drugs in Italy: availability and time-to-access at regional levelGlobal & Regional Health Technology Assessment · 2023
  31. Time to market access in Italy: duration of the P&R process for rare disease drugsGlobal & Regional Health Technology Assessment · 2023
  32. Unmet need: definitions, literature evidence and implications for HTAGlobal & Regional Health Technology Assessment · 2023
  33. Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter membersGlobal & Regional Health Technology Assessment · 2023
  34. Cost-effectiveness of IMI/CIL/REL for the treatment of carbapenem non-susceptible Gram-negative bacterial infectionsGlobal & Regional Health Technology Assessment · 2023
  35. Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosisGlobal & Regional Health Technology Assessment · 2023
  36. Disability weights for castration-resistant prostate cancer: an empirical investigationGlobal & Regional Health Technology Assessment · 2022
  37. Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in ItalyGlobal & Regional Health Technology Assessment · 2022
  38. Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysisGlobal & Regional Health Technology Assessment · 2022
  39. New evidence in adjunctive treatment of focal-onset seizures in adults: a critical appraisalGlobal & Regional Health Technology Assessment · 2022
  40. Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patientGlobal & Regional Health Technology Assessment · 2022
  41. Diagnostic and therapeutic approach to the ACS patientGlobal & Regional Health Technology Assessment · 2022
  42. Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutationsGlobal & Regional Health Technology Assessment · 2022
  43. A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in SpainGlobal & Regional Health Technology Assessment · 2022
  44. Cost-utility analysis of evolocumab in patients with ASCVD in ItalyGlobal & Regional Health Technology Assessment · 2021
  45. Evaluation of epidemiological and economic consequences due to the delay in treatment of hiv-positive patients caused by the covid-19 pandemicGlobal & Regional Health Technology Assessment · 2021
  46. Real-world data: how they can help to improve quality of careGlobal & Regional Health Technology Assessment · 2021
  47. Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in ItalyGlobal & Regional Health Technology Assessment · 2021
  48. Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly populationGlobal & Regional Health Technology Assessment · 2021
  49. Economic Impact of Therapeutic Choices: The Case of IncretinsGlobal & Regional Health Technology Assessment · 2021
  50. Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemiaGlobal & Regional Health Technology Assessment · 2021